Sexually Transmitted Infections: Chlamydia, Gonorrhea, and Syphilis – Clinical Pharmacology and Management

Sexually transmitted infections (STIs) remain a leading cause of morbidity worldwide, with chlamydia, gonorrhea, and syphilis accounting for the majority of reported cases. In 2023 alone, the Centers for Disease Control and Prevention reported over 1.8 million chlamydia infections, 580,000 gonorrhea cases, and 20,000 new syphilis diagnoses in the United States. These numbers translate into significant clinical burden: untreated chlamydia can lead to pelvic inflammatory disease and infertility, gonorrhea may progress to disseminated disease and infertility, and syphilis can cause irreversible neurological damage if left untreated. A recent case series highlighted a 28‑year‑old woman who presented with pelvic pain and was found to have chlamydia and gonorrhea co‑infection, underscoring the importance of prompt, accurate diagnosis and treatment.

Introduction and Background

Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum are the three most frequently reported bacterial STIs. Their epidemiology reflects distinct transmission dynamics and demographic patterns. Chlamydia is the most common bacterial STI worldwide, often asymptomatic in both sexes, with a higher prevalence among adolescents and young adults. Gonorrhea incidence has risen sharply in recent years, partly due to increasing antibiotic resistance. Syphilis, once largely controlled by penicillin, has resurged, especially among men who have sex with men and in communities with limited access to healthcare.

From a pharmacological standpoint, each organism requires a distinct therapeutic approach. Chlamydia is an obligate intracellular pathogen, necessitating antibiotics that penetrate host cells and inhibit protein synthesis. Gonorrhea, a Gram‑negative diplococcus, is treated with agents that disrupt cell wall synthesis or inhibit protein synthesis, but resistance has forced reliance on third‑generation cephalosporins and dual therapy. Syphilis, caused by a spirochete, responds best to beta‑lactam antibiotics that inhibit cell wall synthesis, with penicillin G remaining the gold standard. Understanding the pharmacodynamics and pharmacokinetics of these agents is essential for optimal patient outcomes.

Mechanism of Action

Azithromycin and Doxycycline (Chlamydia)

Azithromycin is a macrolide that binds to the 50S ribosomal subunit, blocking translocation and thereby inhibiting protein synthesis. Its long half‑life and high intracellular accumulation make it ideal for treating intracellular organisms like Chlamydia trachomatis. Doxycycline, a tetracycline, binds to the 30S subunit, preventing aminoacyl‑tRNA attachment and inhibiting protein synthesis. Both antibiotics achieve effective intracellular concentrations, essential for eradicating the pathogen within epithelial cells.

Ceftriaxone (Gonorrhea)

Ceftriaxone is a third‑generation cephalosporin that binds to penicillin‑binding proteins (PBPs) in the bacterial cell wall. Inhibition of transpeptidase activity disrupts peptidoglycan cross‑linking, leading to cell lysis. Its high affinity for PBP2 and PBP3 in Neisseria gonorrhoeae accounts for its potency against this organism, even in the face of emerging resistance.

Azithromycin (Dual Therapy for Gonorrhea)

Azithromycin’s mechanism overlaps with that of doxycycline, targeting the 50S ribosomal subunit. In dual therapy regimens, it provides a complementary mechanism that helps prevent the emergence of resistance by simultaneously targeting two essential bacterial processes.

Penicillin G (Syphilis)

Penicillin G, a narrow‑spectrum beta‑lactam, binds to PBPs in Treponema pallidum, inhibiting peptidoglycan synthesis and causing bacterial cell death. Its efficacy is due to the spirochete’s reliance on cell wall synthesis for maintaining its unique helical shape and motility. Ceftriaxone is used as an alternative for patients with penicillin allergy or for neurosyphilis, where it achieves therapeutic concentrations in cerebrospinal fluid.

Clinical Pharmacology

Pharmacokinetics

Azithromycin: oral bioavailability ~37%, peak plasma concentration 1–2 hr after dosing, volume of distribution 50–70 L, half‑life 68 hr, eliminated primarily by biliary excretion. Doxycycline: oral bioavailability 70–90%, peak concentration 1–2 hr, volume of distribution 0.5–0.8 L/kg, half‑life 18–22 hr, renal excretion. Ceftriaxone: intravenous bioavailability 100%, peak serum concentration 1–2 hr, volume of distribution 0.4–0.5 L/kg, half‑life 8 hr, excreted unchanged by kidneys. Penicillin G: IV bioavailability 100%, peak concentration 1–2 hr, volume of distribution 0.2 L/kg, half‑life 15–30 min in plasma but 1–2 hr in CSF, renal excretion.

Pharmacodynamics

Azithromycin and doxycycline achieve bacteriostatic activity against Chlamydia trachomatis, with MIC90 values <0.25 µg/mL and <0.5 µg/mL respectively. Ceftriaxone demonstrates bactericidal activity against Neisseria gonorrhoeae with MIC90 values <0.025 µg/mL. Penicillin G exhibits bactericidal activity against Treponema pallidum with MIC90 <0.05 µg/mL. The therapeutic window for ceftriaxone is narrow; dosing must achieve serum concentrations above the MIC for at least 30 min to ensure efficacy.

Therapeutic Applications

• Chlamydia trachomatis – Azithromycin 1 g orally single dose or Doxycycline 100 mg orally twice daily for 7 days.

• Neisseria gonorrhoeae – Ceftriaxone 500 mg IM single dose; dual therapy adds Azithromycin 1 g orally single dose.

• Syphilis (early stages) – Penicillin G 2.4 MU IV every 4 hr for 10 days or 14 days for neurosyphilis; Ceftriaxone 1 g IV every 12 hr for 10 days as alternative.

• Syphilis (late stages) – Penicillin G 2.4 MU IV daily for 10 days.

• Pregnancy – Azithromycin 1 g orally single dose for chlamydia; Ceftriaxone 250 mg IM single dose for gonorrhea; Penicillin G 2.4 MU IV every 4 hr for 10 days for syphilis.

• Renal impairment – Dose adjustments for ceftriaxone and penicillin G in severe renal dysfunction; azithromycin and doxycycline generally safe.

• Hepatic impairment – Azithromycin and doxycycline safe; ceftriaxone may accumulate in hepatic failure; penicillin G requires monitoring.

Adverse Effects and Safety

• Azithromycin – GI upset (20–30 %), QT prolongation (rare, <1 %), hepatotoxicity (rare).

• Doxycycline – GI upset (15–25 %), photosensitivity (10 %), teeth discoloration in children (<8 yrs).

• Ceftriaxone – Injection site reactions (10–15 %), cholestatic jaundice (rare), hypersensitivity reactions.

• Penicillin G – Anaphylaxis (rare), serum sickness, neutropenia.

Clinical Pearls for Practice

• Use dual therapy for gonorrhea to curb resistance.

• Azithromycin single‑dose is preferred for chlamydia in patients with non‑compliance.

• Penicillin G remains the gold standard for all stages of syphilis; ceftriaxone is reserved for penicillin‑allergic patients.

• Screen all pregnant women for chlamydia and gonorrhea; treat promptly to prevent neonatal complications.

• Monitor for serum sickness after 1–2 days of penicillin G therapy in syphilis.

• Use the mnemonic “CPS” (Chlamydia, Penicillin, Syphilis) to recall first‑line agents.

• For neurosyphilis, ensure adequate CSF penetration by using penicillin G or ceftriaxone.

• Avoid prescribing doxycycline to children <8 yrs due to teeth discoloration risk.

Comparison Table

Exam‑Focused Review

Common question stems: “Which antibiotic is first‑line for uncomplicated chlamydia?” “What is the recommended therapy for a pregnant patient with gonorrhea?” “Which drug is contraindicated in patients with a penicillin allergy?” “What is the treatment for early syphilis in a non‑pregnant adult?”

Key differentiators students often confuse: azithromycin vs doxycycline for chlamydia; ceftriaxone vs penicillin G for syphilis; dual therapy vs single‑dose for gonorrhea. Remember that penicillin G is the standard for syphilis regardless of stage, while ceftriaxone is reserved for neurosyphilis or penicillin‑allergic patients.

Must‑know facts for NAPLEX/USMLE/clinical rotations:

• Azithromycin 1 g PO single dose is FDA‑approved for uncomplicated chlamydia.

• Ceftriaxone 500 mg IM single dose plus azithromycin 1 g PO single dose is CDC‑recommended dual therapy for gonorrhea.

• Penicillin G 2.4 MU IV every 4 hr for 10 days is the gold standard for early syphilis.

• For neurosyphilis, penicillin G 4 MU IV every 4 hr or ceftriaxone 1 g IV every 12 hr for 10 days.

• Avoid doxycycline in children <8 yrs due to risk of permanent teeth discoloration.

Key Takeaways

1. Chlamydia is best treated with azithromycin 1 g PO single dose or doxycycline 100 mg BID for 7 days.

2. Gonorrhea requires ceftriaxone 500 mg IM single dose plus azithromycin 1 g PO single dose.

3. Syphilis, regardless of stage, is treated with penicillin G 2.4 MU IV every 4 hr for 10 days.

4. Ceftriaxone is an alternative for neurosyphilis or penicillin‑allergic patients.

5. Azithromycin’s long half‑life provides excellent intracellular penetration for chlamydia.

6. Doxycycline’s photosensitivity risk necessitates sun protection counseling.

7. Monitor for serum sickness after 1–2 days of penicillin G therapy in syphilis.

8. Screen and treat pregnant women for chlamydia and gonorrhea to prevent neonatal complications.

9. Use dual therapy for gonorrhea to mitigate the rise in antibiotic resistance.

10. Avoid doxycycline in children <8 yrs to prevent teeth discoloration.

Always confirm diagnosis with nucleic acid amplification testing before initiating therapy, and counsel patients on safe sexual practices to reduce reinfection rates.